|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Guanfacine#Nonclinical Toxicology]] |
| {{Guanfacine}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Nonclinical Toxicology==
| |
| | |
| ===13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility===
| |
| | |
| ====Carcinogenesis====
| |
| No carcinogenic effect of guanfacine was observed in studies of 78 weeks in mice or 102 weeks in rats at doses up to 6-7 times the maximum recommended human dose of 4 mg/day on a mg/ m2 basis.
| |
| | |
| ====Mutagenesis====
| |
| Guanfacine was not genotoxic in a variety of test models, including the Ames test and an in vitro chromosomal aberration test; however, a marginal increase in numerical aberrations (polyploidy) was observed in the latter study.
| |
| | |
| ====Impairment of Fertility====
| |
| No adverse effects were observed in fertility studies in male and female rats at doses up to 30 times the maximum recommended human dose on a mg/ m2 basis.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = INTUNIV (GUANFACINE) TABLET, EXTENDED RELEASE INTUNIV (GUANFACINE) KIT [SHIRE US MANUFACTURING INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b972af81-3a37-40be-9fe1-3ddf59852528#section-12.1 | publisher = | date = | accessdate = 25 February 2014 }}</ref>
| |
| | |
| ==References==
| |
| {{reflist|2}}
| |
| | |
| {{Antihypertensives and diuretics}}
| |
| {{Antihyperkinetics}}
| |
| {{Adrenergics}}
| |
| | |
| [[Category:Antihypertensive agents]]
| |
| [[Category:Guanidines]]
| |
| [[Category:Alpha-adrenergic agonists]]
| |
| [[Category:Acetamides]]
| |
| [[Category:Organochlorides]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |